The clinical data is clearly positive and the financing removes near-term bankruptcy risk, but the massive warrant overhang (39.6M common warrants vs 4.2M shares outstanding) will cap upside. Watch for ASCO 2026 presentation on June 1 for additional efficacy data. The stock may trade on pipeline milestones rather than financials; the key binary event is the FDA accelerated approval filing timeline.
Price Chart
Executive Summary
Cellectar Biosciences reported Q1 2026 net loss of $5.7M ($1.33/share), narrower than the $6.6M loss ($4.30/share) in Q1 2025, but the key catalyst is the positive 12-month follow-up data from the CLOVER WaM Phase 2b study for iopofosine I 131, which supports a planned accelerated approval filing with the FDA. The company also completed a $35M upfront (up to $140M total) financing led by top healthcare investors, extending its cash runway into Q2 2027 and funding the Phase 3 confirmatory study. However, the massive dilution from the May 2026 offering (including 9.5M prefunded warrants and 39.6M common warrants) creates significant overhang for existing shareholders.
Key Financial Metrics
Key Facts
- Net loss for Q1 2026 was $5.7M ($1.33/share) vs $6.6M ($4.30/share) in Q1 2025
- Cash and cash equivalents of $8.3M as of March 31, 2026, before $31M net proceeds from May 2026 offering
- Positive 12-month follow-up data from CLOVER WaM Phase 2b study: 61.8% major response rate, 83.6% overall response rate, median PFS 13.5 months
- Completed $35M upfront (up to $140M total) financing led by Nantahala Capital, Balyasny, Caligan, Janus Henderson, SilverArc
- Plans to initiate Phase 3 confirmatory study and file for accelerated approval with FDA for iopofosine I 131 in WM
- May 2026 offering includes 9.5M prefunded warrants and 39.6M common warrants creating massive dilution overhang
- ASCO 2026 poster presentation selected for CLOVER WaM subgroup data on June 1, 2026
- First patients dosed in Phase 1b CLR 125 study for triple negative breast cancer
Financial Impact
Q1 2026 net loss improved to $5.7M from $6.6M YoY; cash burn rate ~$1.9M/month; $31M net proceeds from May offering extends runway to Q2 2027
Risk Factors
- Massive dilution from 39.6M common warrants and 9.5M prefunded warrants in May 2026 offering
- Phase 3 confirmatory study requires ~18-24 months enrollment — long timeline to approval
- No revenue and ongoing cash burn; additional capital likely needed before commercialization
- FDA accelerated approval not guaranteed despite positive Phase 2b data
- Competition from BTK inhibitors and other WM therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-060693 |
| Document: tm2614602d1_8k.htm | 0001104659-26-060693 |
| Document: 0001104659-26-060693-index-headers.html | 0001104659-26-060693 |
| Document: 0001104659-26-060693-index.html | 0001104659-26-060693 |
| Document: 0001104659-26-060693.txt | 0001104659-26-060693 |
| 8-K Data (Synthetic) | 0001104659-26-060693 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | Press Release | $1.19 | awaiting T+60 | — | $1.22 (+2.52%) |
Aug 13, 2026 10w ago | 8-K | $2.48 | awaiting T+60 | — | $1.22 (−50.81%) |
Aug 13, 2026 10w ago | Press Release | $2.48 | awaiting T+60 | — | $1.22 (−50.81%) |
Jun 1, 2026 21w ago | Press Release | $2.97 $2.54 | ▼ −14.48% | ▼ −15.71% | $1.22 (−58.92%) |
May 29, 2026 21w ago | S-1/A | $3.14 $2.52 | ▲ +19.75% | ▲ +20.93% | $1.22 (+61.15%) |
May 28, 2026 21w ago | DEFA14A | $3.14 $2.52 | ▼ −19.75% | ▼ −20.93% | $1.22 (−61.15%) |
May 19, 2026 22w ago | S-1 | $3.17 $2.60 | ▲ +17.98% | ▲ +22.98% | $1.22 (+61.51%) |
May 14, 2026 23w ago | 8-K | $3.20 $2.60 | ▼ −18.75% | ▼ −22.34% | $1.22 (−61.87%) |
May 14, 2026 23w ago | Press Release | $3.20 $2.60 | ▼ −18.75% | ▼ −22.34% | $1.22 (−61.87%) |
May 11, 2026 24w ago | Press Release | $3.06 $2.52 | ▼ −17.65% | ▼ −22.04% | $1.22 (−60.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers